These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 16022920)

  • 21. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
    Fujiwara K; Ueoka H; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Sugimoto K; Shibayama T; Kamei H; Harita S; Okimoto N; Tanimoto M
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):755-60. PubMed ID: 16208519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
    Ardizzoni A; Favaretto A; Boni L; Baldini E; Castiglioni F; Antonelli P; Pari F; Tibaldi C; Altieri AM; Barbera S; Cacciani G; Raimondi M; Tixi L; Stefani M; Monfardini S; Antilli A; Rosso R; Paccagnella A
    J Clin Oncol; 2005 Jan; 23(3):569-75. PubMed ID: 15659503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
    Frasci G; Nicolella G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Natale M; Piantedosi F; Russo A; Palmeri S; Comella G; Panza N
    Br J Cancer; 2001 May; 84(9):1166-71. PubMed ID: 11336465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
    Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
    O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
    Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
    Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B
    Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
    Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P
    Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
    Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging role of weekly topotecan in recurrent small cell lung cancer.
    Eckardt JR
    Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
    Einhorn LH; Loehrer PJ
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):28-31. PubMed ID: 7846539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.